Pluri Inc
NASDAQ:PLUR 12:58:41 AM EDT
| Market Cap (Intraday) | 45.28M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.04 |
| 50-Day MA | $4.85 |
| 200-Day MA | $4.73 |
Pluri Inc Stock, NASDAQ:PLUR
MATAM Advanced Technology Park, Building No. 5, Haifa, Haifa 3508409
Israel
Phone: +972.74.710.8600
Number of Employees: 118
Description
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.